Caki-1 Cell Lysate: sc-2224

The Caki-1 Cell Lysate is derived from the Caki-1 cell line, which originates from a human renal carcinoma. This lysate is a complex blend of cellular constituents including proteins, nucleic acids, lipids, and metabolites, obtained through methods such as mechanical disruption, detergent lysis, or enzymatic breakdown. It captures a broad spectrum of the cellular machinery and is extensively utilized in research fields that explore basic cellular functions and mechanisms. The Caki-1 Cell Lysate provides an essential resource for studying cellular dynamics and biochemistry, particularly in the context of renal cell characteristics and behavior. It is instrumental in biochemical and molecular biology research, enabling the study of protein pathways, gene expression, and cellular responses to various stimuli in a controlled environment. This lysate aids in understanding how renal cells interact within their microenvironment, manage waste products, and regulate electrolyte balance. Additionally, it is commonly used in proteomics to analyze protein expression and interactions, helping researchers identify and quantify the presence of specific proteins. By allowing for a detailed examination of the biochemical and genetic underpinnings of renal cells, Caki-1 Cell Lysate supports a wide array of non-medical research endeavors that aim to explain fundamental processes impacting cell biology and physiology.

Caki-1 Cell Lysate References:

1. CDP-choline significantly restores phosphatidylcholine levels by differentially affecting phospholipase A2 and CTP: phosphocholine cytidylyltransferase after stroke.  |  Adibhatla, RM., et al. 2006. J Biol Chem. 281: 6718-25. PMID: 16380371
2. Effect of tricyclodecan-9-yl potassium xanthate (D609) on phospholipid metabolism and cell death during oxygen-glucose deprivation in PC12 cells.  |  Larsen, EC., et al. 2007. Neuroscience. 146: 946-61. PMID: 17434680
3. AIF downregulation and its interaction with STK3 in renal cell carcinoma.  |  Xu, S., et al. 2014. PLoS One. 9: e100824. PMID: 24992339
4. Impaired salivary gland activity in patients with autoimmune polyendocrine syndrome type I.  |  Oftedal, BE., et al. 2017. Autoimmunity. 50: 211-222. PMID: 28686485
5. Combination therapy using molecular-targeted drugs modulates tumor microenvironment and impairs tumor growth in renal cell carcinoma.  |  Kitano, H., et al. 2017. Cancer Med. 6: 2308-2320. PMID: 28834289
6. Upregulation of DR5 and Downregulation of Survivin by IITZ-01, Lysosomotropic Autophagy Inhibitor, Potentiates TRAIL-Mediated Apoptosis in Renal Cancer Cells via Ubiquitin-Proteasome Pathway.  |  Shahriyar, SA., et al. 2020. Cancers (Basel). 12: PMID: 32825566
7. RNA-binding protein SORBS2 suppresses clear cell renal cell carcinoma metastasis by enhancing MTUS1 mRNA stability.  |  Lv, Q., et al. 2020. Cell Death Dis. 11: 1056. PMID: 33311452
8. Pathogen-Mimicking MnO Nanoparticles for Selective Activation of the TLR9 Pathway and Imaging of Cancer Cells  |  Shukoor, M. I., Natalio, F., Tahir, M. N., Wiens, M., Tarantola, M., Therese, H. A.,.. & Tremel, W. 2009. Advanced functional materials. 19(23): 3717-3725.